Abstract
The combination of cilgavimab-tixagevimab (Evusheld™, Astra Zeneca) became the mainstay for protecting transplant recipients with poor response to vaccination against the omicron variant. Serum neutralizing capacity against SARS-CoV-2 is positively associated with protection against severe forms of Covid-19.
Both anti-RBD IgG titers and neutralizing antibody titers against the omicron BA.1 variant were measured in serum samples collected from 63 adult kidney transplant recipients who received prophylactic injections of Evusheld™. Patients who received prophylactic Ronapreve™ (casirivimab-imdevimab, n = 39) and those who were infected with SARS-CoV-2 during the fifth wave of the pandemic (n = 14) served as negative and positive controls, respectively.
After a median interval from injection of 29 days (interquartile range 29-33 days), only 9.5% of patients who received Evusheld™ were able to neutralize the omicron variant compared to 71% of patients who were infected with SARS-CoV-2 and 2.6% of those who received Ronapreve™. Interestingly, convalescent patients displayed higher levels of neutralizing antibodies than those who received EvusheldTM (median: 2.3 log IC50, IQR: 1.5-2.7 versus 0.00 log IC50, IQR: 0&[ndash] 0.05; p<0.001). A high interindividual variability in anti-RBD IgG titers was observed after Evusheld™ (range: 262-7032 BAU/mL). This variability was largely explained by the patients’body mass index, which showed an inverse correlation with anti-RBD IgG titers.
These findings suggest that Evusheld™ given at a dose of 300 mg is not sufficient to elicit an anti-RDB titer that confers in vivo neutralizing activity and support recent FDA recommendations, derived from in vitro models, regarding the need to increase the dose of Evusheld™
Introduction
Kidney transplant recipients show an impairment of vaccine-induced immune response, resulting in an increased risk of severe Covid-19 (1). In an effort to address this issue, health authorities have authorized the use of anti-SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis. While the combination of casirivimab–imdevimab (Ronapreve™, Roche Regeneron) has been shown to confer satisfactory protection against the delta variant (2), it has limited neutralizing activity against omicron (3). Consequently, as of December 2021, the combination of cilgavimab–tixagevimab (Evusheld™, Astra Zeneca) became the mainstay for protecting transplant recipients with poor response to vaccination against the omicron variant. Serum neutralizing capacity against SARS-CoV-2 is positively associated with protection against severe forms of Covid-19, including the kidney transplant recipients population (4).
Patients and Methods
Both anti-RBD IgG titers and neutralizing antibody titers against the omicron BA.1 variant were measured in serum samples collected from 63 adult kidney transplant recipients who received intramuscular prophylactic injections of Evusheld™ (150 mg tixagevimab and 150 mg cilgavimab) in the Lyon and Strasbourg University Hospitals. Cases with a history of Covid-19 or positive anti-nucleocapsid IgG were excluded. Patients who received prophylactic Ronapreve™ (600 mg casirivimab and 600 mg imdevimab, n = 39) and those who were infected with SARS-CoV-2 during the fifth wave of the pandemic (n = 14) served as negative and positive controls, respectively. Ethical approval for this study was obtained from the local Ethics Committees (identifiers: DC-2013-1990, Lyon University Hospital and CE-2021-9, Strasbourg University).
Results
After a median interval from injection of 29 days (interquartile range [IQR]: 29-33 days), patients who received Evusheld™ had a low neutralizing activity (Figure 1A) and only 9.5% of them (6/63) were able to neutralize the omicron variant compared to 71% of patients [10/14] who were infected with SARS-CoV-2 and 2.6% [1/39] of those who received Ronapreve™. Interestingly, convalescent patients displayed higher levels of neutralizing antibodies than those who received Evusheld™ (median: 2.3 log IC50, IQR: 1.5-2.7 versus log IC50, IQR: 0-0.05; p<0.001). While anti-RBD IgG titers were generally low after Evusheld™ injection (median: 2583 binding antibody unit (BAU)/mL, IQR: 1906-3611 BAU/mL), a high interindividual variability was observed (range: 262-7032 BAU/mL, Figure 1B). This variability was largely explained by the patients’ body mass index, which showed an inverse correlation with anti-RBD IgG titers (Figure 1C). Further analysis revealed that patients with anti-RBD titers <2500 BAU/mL after Evusheld™ injection had no neutralizing activity (Figure 2). Furthermore, seven patients in this cohort developed symptomatic Covid-19 including two who required hospitalization. All had negative neutralizing activity at the time of diagnosis.
Discussion
The results of our study indicate that less than 10% of patients who received Evusheld™ were able to neutralize the omicron BA.1 variant at 29 post-injection days. These findings suggest that Evusheld™ given at a dose of 300 mg is not sufficient to elicit an anti-RDB titer that confers in vivo neutralizing activity. This is in line with a recent study showing that anti-RBD levels of approximately 8500 BAU/mL were associated with serum neutralizing activity against omicron in transplant recipients who received three vaccine doses (5). Our data also support recent FDA recommendations (6), derived from in vitro models, regarding the need to increase the dose of Evusheld™.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Conflict of Interest Statement
Sophie Caillard and Olivier Thaunat have received consultancy fees from Astra Zeneca. The other authors have no conflicts of interest to declare.